Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in CanadaLONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE ...

Kolkata: The National Pharmaceutical Pricing Authority (NPPA), in an order dated March 27, changed the prices of 80 medicines ...

KLOXXADO® delivers 8 mg of naloxone hydrochloride per spray in a ready to use nasal spray to reverse the effects of opioid overdose. “The approval of KLOXXADO® Nasal Spray will provide ...

KLOXXADO® delivers 8 mg of naloxone hydrochloride per spray in a ready to use nasal spray to reverse the effects of opioid overdose.

The National List of Essential Medicines includes crucial medicines used in different scenarios, including drugs used for ...

The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for RosaceaEmrosi Initial Distribution Ongoing; First ...

The Food and Drug Administration (FDA) has expanded the list of medicines for non-communicable diseases (NCDs) exempted from ...

Health Canada approves Hikma Pharma’s Kloxxado nasal spray 8 mg for treatment of known or suspected opioid overdose: London Monday, March 24, 2025, 13:00 Hrs [IST] Hikma Pharmac ...

In a major leadership transition, HCL Group founder Shiv Nadar has transferred ... On Friday, Lupin launched rivaroxaban tablets USP, 2.5 mg, in the US market. This was followed after the final ...